MedTrace Logo

OMT-111 for Terminal Stage Solid Tumors

NCT04520386 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2020-09-09

No results posted yet for this study

Summary

Patients with terminal stage of metastatic non-small cell lung cancer, metastatic triple negative breast cancer, or advanced or metastatic pancreatic adenocarcinoma resisting to standard therapies.

Conditions

Interventions

DRUG

OMT-111

Pre-filled Syringe

Sponsors & Collaborators

  • MetiMedi Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Soobong Park · MetiMedi Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2022-06-30
Completion
2022-10-31

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520386 on ClinicalTrials.gov